Skip to content

Dr. Reddy’s to market store-brand Prevacid

Dr. Reddy’s Laboratories has launched over-the-counter lansoprazole delayed-release capsules in the U.S. market. The company said Monday that its 15-mg lansoprazole capsules come in pack sizes of 14-, 28- and 42-count and will be marketed under store brand labels in the United States.

Table of Contents

HYDERABAD, India — Dr. Reddy’s Laboratories has launched over-the-counter lansoprazole delayed-release capsules in the U.S. market.

The company said Monday that its 15-mg lansoprazole capsules come in pack sizes of 14-, 28- and 42-count and will be marketed under store brand labels in the United States.

According to Dr. Reddy’s, the product is the bioequivalent version of Novartis Consumer Health’s Prevacid 24HR capsule, which received prescription-to-OTC switch approval with three-year exclusivity from the Food and Drug Administration in March 2009.

Sales of Prevacid 24HR capsules totaled about $115 million for the 12 months ended in March 2012, according to SymphonyIRI data cited by Dr. Reddy’s.

A proton pump inhibitor, lansoprazole reduces the amount of acid produced in the stomach and is indicated for the treatment and prevention of stomach and intestinal ulcers, erosive esophagitis and other conditions involving excessive stomach acid.

Comments

Latest

FMI: Private brands take hold

FMI: Private brands take hold

Perceptions around private brands have changed; they are no longer seen merely as generics or national brand equivalents, Doug Baker, vice president, industry relations at FMI, said in releasing the report, titled “The Power of Private Brands 2024.”